Announcements Trials
Browse Landscape

Phase

Phase 3 3

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 4Genitourinary 3Breast 3Gastrointestinal 2Gynecologic 1

Conditions

Breast Neoplasms 3

Interventions

Trastuzumab 9Paclitaxel 8Capecitabine 8trastuzumab deruxtecan 7Fulvestrant 7pertuzumab 5eribulin 5Gemcitabine 5Cyclophosphamide 5130-nm albumin-bound paclitaxel 5Doxorubicin 4Carboplatin 4Ado-Trastuzumab Emtansine 4sacituzumab govitecan 3ribociclib 3Vinorelbine 3Epirubicin 3Docetaxel 3selpercatinib 2pembrolizumab 2palbociclib 2olaparib 2neratinib 2larotrectinib 2exemestane 2capivasertib 2abemaciclib 2Letrozole 2Fluorouracil 2Anastrozole 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has announcements × Docetaxel × Breast × Clear all
NCT01358877 2025-11-28

APHINITY

Hoffmann-La Roche

Phase 3 Completed
4,804 enrolled 45 charts 1 FDA
Breast

Breast Neoplasms

NCT03493854 2024-06-26

FeDeriCa

Hoffmann-La Roche

Phase 3 Completed
500 enrolled 28 charts 1 FDA
Breast

Breast Neoplasms

NCT00950300 2018-01-23

A Study to Compare Subcutaneous (SC) Versus Intravenous (IV) Administration of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer

Hoffmann-La Roche

Phase 3 Completed
596 enrolled 31 charts 1 FDA
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡